Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.

McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR.

Osteoporos Int. 2013 Jan;24(1):301-10. doi: 10.1007/s00198-012-2175-7.

2.

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.

Osteoporos Int. 2013 Jan;24(1):293-9. doi: 10.1007/s00198-012-2056-0.

3.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group.; International Breast Cancer Study Group (IBCSG)..

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4.

4.

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.

McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR.

Osteoporos Int. 2012 Jan;23(1):267-76. doi: 10.1007/s00198-011-1791-y.

5.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups..

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6.

6.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group., Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

7.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group.; BIG 1-98 Collaborative Group..

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.

8.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups..

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033.

9.

Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.

Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.

Clin Ther. 2009 Feb;31(2):272-85. doi: 10.1016/j.clinthera.2009.02.012.

PMID:
19302900
10.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98..

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829.

11.

Characterization of human hair melanin and its degradation products by means of magnetic resonance techniques.

Ghiani S, Baroni S, Burgio D, Digilio G, Fukuhara M, Martino P, Monda K, Nervi C, Kiyomine A, Aime S.

Magn Reson Chem. 2008 May;46(5):471-9. doi: 10.1002/mrc.2202.

PMID:
18288677
12.

Synthesis and characterization of a Gd(III) based contrast agent responsive to thiol containing compounds.

Carrera C, Digilio G, Baroni S, Burgio D, Consol S, Fedeli F, Longo D, Mortillaro A, Aime S.

Dalton Trans. 2007 Nov 21;(43):4980-7.

PMID:
17992283
13.

Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.

Racewicz AJ, Schofield PJ, Cahall DL, Cline GA, Burgio DE.

Curr Med Res Opin. 2007 Dec;23(12):3079-89.

PMID:
17971285
14.

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S.

Bone. 2008 Jan;42(1):36-42.

PMID:
17920005
15.

Functional outcomes of the retromaxillary-infratemporal fossa dissection for advanced head and neck/skull base lesions.

Shibuya TY, Doerr TD, Mathog RH, Burgio DL, Meleca RJ, Yoo GH, Guthikonda M.

Skull Base Surg. 2000;10(3):109-17.

16.
17.

Responses from US readers to the Webcast video editorial entitled "American Healthcare is the best in the world if...".

Bansal N, Greif EE, Bosch R, Holland JD, Dixon T, Cohen SD, Hernandez M, Reisman EM, Burgio D, Peckham C, Hennenfent B, Garcia MA, Govatos J, Morton ML.

MedGenMed. 2004 Sep 28;6(3):26. No abstract available.

18.

WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.

Church MW, Blakley BW, Burgio DL, Gupta AK.

J Assoc Res Otolaryngol. 2004 Sep;5(3):227-37.

19.

Titanium mesh repair of the severely comminuted frontal sinus fracture.

Lakhani RS, Shibuya TY, Mathog RH, Marks SC, Burgio DL, Yoo GH.

Arch Otolaryngol Head Neck Surg. 2001 Jun;127(6):665-9.

PMID:
11405865
20.

Evaluation of hydroxyapatite ossicular chain prostheses.

Pasha R, Hill SL 3rd, Burgio DL.

Otolaryngol Head Neck Surg. 2000 Oct;123(4):425-9.

PMID:
11020179

Supplemental Content

Loading ...
Support Center